The objectives of the study were to analyze 1) compliance with an HMG-CoA reductase inhibitor, 2) the relationship between treatment compliance and sociodemographic, clinical, and psychological criteria, and 3) the effect of raising patients'awareness through distribution of an information notice.
The results analyzed in this article compare the noncompliant and compliant population independently of awareness.
This open-label study was conducted in two randomized parallel groups : a control group that received the information normally given by the practitioners, and an awareness group that received specific informational brochures on diet and cardiovascular risk factors and the reasons for the treatment.
Male and female patients (n=3845) aged 18 to 75 years with primary hypercholesterolemia (type IIa and IIb), not taking a cholesterol-lowering drug or for whom an ongoing treatment was poorly tolerated or ineffective, were to be included.
Cholesterol levels had to be greater than 250 mg/dL (or 200 mg/dL if previous coronary history) and triglyceride levels less than 350 mg/dL.
A total of 2888 subjects (75%) were defined as compliant (taking more than 90% of the prescription) and 957 (25%) noncompliant.
Both populations are identical for age, sex ratio, and different risk factors, with the exception of diabetes. (...)
Mots-clés Pascal : Hypercholestérolémie, Homme, Traitement, Fluvastatine, Chimiothérapie, Hypolipémiant, Inhibiteur enzyme, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Evolution, Complaisance, Etude longitudinale, Education santé, Recommandation, Relation médecin malade, France, Europe, Epidémiologie, Lipide, Métabolisme pathologie, Dyslipémie, Hyperlipoprotéinémie
Mots-clés Pascal anglais : Hypercholesterolemia, Human, Treatment, Fluvastatin, Chemotherapy, Antilipemic agent, Enzyme inhibitor, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Evolution, Compliance, Follow up study, Health education, Recommendation, Physician patient relation, France, Europe, Epidemiology, Lipids, Metabolic diseases, Dyslipemia, Hyperlipoproteinemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0393971
Code Inist : 002B02N. Création : 22/03/2000.